NewBridge Pharmaceuticals
NewBridge Pharmaceuticals is a Dubai-based specialty pharmaceutical company that in-licenses FDA/EMA-approved therapeutics from global pharma and commercializes them across the MENA region through in-house regulatory, market access, medical affairs, and distribution operations. It serves patients and healthcare providers in twelve MENA markets and holds partnerships with Lundbeck, BeiGene, Agios, BioCryst, and others.
- Company typePrivate
- Founded2010
- HeadquartersDubai, United Arab Emirates
- Headcount51–100
- GTM typeB2B
- OfferingServices
What NewBridge Pharmaceuticals does
NewBridge Pharmaceuticals is a Dubai-headquartered specialty pharmaceutical commercialization platform founded in 2010 to bridge the access gap between global pharmaceutical innovation and patients across the Middle East and North Africa (MENA) region. The company in-licenses FDA or EMA approved therapeutics from global pharma and biotech partners and handles the full commercialization lifecycle through in-house capabilities spanning regulatory affairs, market access, medical affairs, sales and marketing, supply chain and logistics, pharmacovigilance, quality, and legal/compliance. Its product portfolio comprises 31 brands across six therapeutic verticals — rare disease, oncology/hematology, neuroscience, immunology, gastroenterology, and genomics/diagnostics — sourced from partners including Agios, BeiGene, BioCryst, Biogen, Kyowa Kirin, Lundbeck, Hansa Biopharma, Pharming, Sunovion, UCB, Madrigal, and others.
The company generates revenue primarily through licensing and distribution agreements that pay NewBridge a margin or royalty on sales of partner products in MENA markets, supplemented by managed services revenue from Early Access Programs that supply unregistered medicines to MENA patients on a named-patient basis before local regulatory approval. Distribution is executed both directly to hospitals, clinics, and pharmacies through the company's own sales infrastructure and via a logistics partnership with Aramex for temperature-controlled cold chain shipments originating from UK and Canada distribution hubs. Strategic differentiation rests on the company's claimed first-mover position as a MENA-focused commercialization intermediary and on established relationships with regulators including the Saudi Food and Drug Authority and UAE Ministry of Health and Prevention.
NewBridge operates from offices in seven markets — Dubai (HQ and GCC office), Jeddah, Riyadh, Beirut (Levant), Cairo (Egypt and Libya), Casablanca (North Africa), and Kuwait — and reports distribution coverage across 12 MENA countries including Bahrain, Qatar, Oman, Iraq, and Jordan. The company employs 55 people representing 42 nationalities (2022 data) and has disclosed $60 million in cumulative equity funding across two rounds (2010 seed led by Kuwait Life Sciences Company and a 2013 Series 3 led by Elan Corporation with participation from Burrill & Company and KLSC). Institutional shareholders disclosed on the company website include Kuwait Investment Authority (sovereign wealth, via National Technology Enterprises Company), Perrigo Company, and Burrill Life Sciences Capital Fund III. The most recent strategic events — the November 2025 absorption of Lundbeck's MENA commercial operations, the March 2026 Madrigal MASH distribution agreement, and first-in-region regulatory approvals for PYRUKYND — indicate active commercial scaling rather than maturity.
NewBridge Pharmaceuticals firmographics
Firmographics- Name
- NewBridge Pharmaceuticals
- Legal name
- NewBridge Pharmaceuticals FZ LLC
- Website
- https://nbpharma.com
- Company type
- Private
- Founded year
- 2010
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- NewBridge Pharmaceuticals is a Dubai-based specialty pharmaceutical company that in-licenses FDA/EMA-approved therapeutics from global pharma and commercializes them across the MENA region through in-house regulatory, market access, medical affairs, and distribution operations. It serves patients and healthcare providers in twelve MENA markets and holds partnerships with Lundbeck, BeiGene, Agios, BioCryst, and others.
- Ownership category
- akta.pro rank
NewBridge Pharmaceuticals industry classification
Industry- Product category
- Specialty Pharmaceutical Commercialization
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industry
- Nephrology & Urology Specialty Pharmaceuticals (HLAIACAH)
Keywords
Where NewBridge Pharmaceuticals is headquartered
LocationHeadquarters
- HQ city
- Dubai
- HQ country
- United Arab Emirates
- HQ region
- Middle East
Offices7 records
Markets served
NewBridge Pharmaceuticals business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Product Commercialization: Revenue generated through distribution and licensing agreements with global pharma and biotech companies for commercializing innovative therapeutics in the MENA region. NewBridge commercializes products for partners including Agios (PYRUKYND), BioCryst (ORLADEYO), BeiGene (BRUKINSA), and others.
- Early Access Program: Early access programs provide medicines to patients before local regulatory approval is obtained, generating revenue through named patient supply arrangements.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
NewBridge Pharmaceuticals product offering
Product offeringCore offering
NewBridge Pharmaceuticals is a specialty pharmaceutical commercialization platform that in-licenses, registers, and distributes FDA/EMA-approved innovative therapeutics from global pharma and biotech companies across the Middle East and North Africa. Its core activity is providing end-to-end regional commercialization — regulatory affairs, market access, medical affairs, sales and marketing, supply chain, pharmacovigilance, and quality compliance — for partner products spanning rare disease, oncology, hematology, neuroscience, immunology, gastroenterology, and genomics. The company also operates Early Access Programs that supply unregistered medicines to patients before local regulatory approval.
Product overview
NewBridge Pharmaceuticals is a regional specialty pharmaceutical company serving the Middle East and North Africa (MENA) region. It operates as a first-in-class commercialization platform focused on in-licensing and commercializing innovative FDA or EMA-approved therapeutics developed by global pharmaceutical companies. The company offers a comprehensive pharmaceutical platform with in-house capabilities including Regulatory Affairs, Market Access, Medical Affairs, Early Access Programs, Sales & Marketing, Finance, Supply Chain & Logistics, Pharmacovigilance, Quality, Legal & Compliance, IT, and HR. The product portfolio includes specialty pharmaceuticals across therapeutic areas such as Gastroenterology, Genomics, Immunology, Neuroscience, Oncology/Hematology, and Rare Disease. Key products include PYRUKYND (mitapivat) for thalassemia and PK deficiency, BRUKINSA (zanubrutinib) for mantle cell lymphoma, ORLADEYO (berotralstat) for hereditary angioedema, RUCONEST (conestat alfa) for HAE, Latuda (lurasidone) for schizophrenia, and various rare disease treatments including CRYSVITA and POTELIGEO from Kyowa Kirin. The company commercializes these products through partnerships with global pharma and biotech companies, providing access to innovative medicines for patients in the MENA region.
Differentiator
Problem solved
Functional benefit
Products and services
- PYRUKYND (mitapivat) PYRUKYND is a pyruvate kinase activator indicated for treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency and for adult patients with non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, distributed by NewBridge in the GCC region under license from Agios Pharmaceuticals.
- BRUKINSA (zanubrutinib) BRUKINSA is a next-generation BTK inhibitor for treatment of mantle cell lymphoma (MCL) in adult patients who have received at least one prior therapy, distributed by NewBridge in the MENA region under license from BeiGene.
- ORLADEYO (berotralstat) ORLADEYO is the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older, distributed by NewBridge in UAE, GCC, and Iraq under license from BioCryst Pharmaceuticals.
- RUCONEST (conestat alfa) RUCONEST is a plasma-free recombinant human C1 esterase inhibitor (rhC1INH) protein replacement therapy approved for treatment of acute hereditary angioedema (HAE) attacks in adults and children aged two years and over, distributed in MENA by NewBridge under license from Pharming Group.
- Latuda (lurasidone) Latuda is an atypical antipsychotic for treatment of schizophrenia in adults aged 18 years and over, distributed by NewBridge in the GCC Region under license from Sunovion Pharmaceuticals Europe.
- Cimzia (certolizumab pegol) Cimzia is a TNF inhibitor for treatment of moderate to severe rheumatoid arthritis, provided through NewBridge's partnership with UCB.
- Biogen Multiple Sclerosis Products Various multiple sclerosis therapies from Biogen International GmbH distributed by NewBridge in selected MENA countries.
- Idefirix (imlifidase) Idefirix is a novel treatment for desensitization in kidney transplantation, supplied by Hansa Biopharma to the MENA region through NewBridge.
- CRYSVITA (burosumab) CRYSVITA is a recombinant human monoclonal antibody that binds to FGF23 for treatment of X-Linked Hypophosphataemia (XLH) and Tumour-Induced Osteomalacia (TIO), distributed by NewBridge in Algeria, Iraq, Libya, and Jordan under license from Kyowa Kirin International.
- POTELIGEO (mogamulizumab) POTELIGEO is a first-in-class humanized monoclonal antibody directed against CCR4 for treatment of cutaneous T-cell lymphoma (CTCL), distributed by NewBridge in Algeria, Iraq, Libya, and Jordan under license from Kyowa Kirin International.
- Madrigal MASH Treatments Metabolic Dysfunction-Associated Steatohepatitis (MASH) treatments from Madrigal Pharmaceuticals to be distributed in the MENA region through NewBridge.
- Abstral Abstral is a fast-acting sublingual tablet for treating pain in cancer patients.
- Neupro Neupro is a patch used to treat signs and symptoms of idiopathic Parkinson's disease.
- Halaven (eribulin) Halaven (eribulin) is a chemotherapy agent for patients with metastatic breast cancer.
- Oncotype DX Oncotype DX is a diagnostic test for patients with early-stage breast cancer that helps guide treatment decisions.
- Lacosamide Lacosamide is a treatment used as adjunctive therapy for partial onset seizures in epilepsy.
- Early Access Program (Named Patient Supply) Service allowing expert physicians in MENA countries to formally request essential unregistered medications on behalf of individual patients before local regulatory approval, in compliance with local laws and regulations and in coordination with health authorities and business partners.
Quantifiable outcome
- Successfully commercialized PYRUKYND in UAE and Saudi Arabia for thalassemia patients
- +1 more outcomes
Companies that use NewBridge Pharmaceuticals
Customer profileNamed customers4 records
Segments6 records
Ideal customer profiles3 records
NewBridge Pharmaceuticals technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
NewBridge Pharmaceuticals partnerships and signals
Strategic signalPartnerships
16 partnerships are on record, tiered core and minor.
- Madrigal PharmaceuticalscoreDistribution agreement for MASH (Metabolic Dysfunction-Associated Steatohepatitis) therapeutics in the MENA region, reinforcing commitment to improving access to innovative therapies for patients with serious liver diseases.
- LundbeckcoreOfficial transition of Lundbeck's commercial operations in MENA region to NewBridge Pharmaceuticals, marking the start of key partnership for neuroscience products in the Middle East and North Africa.
- Kyowa Kirin InternationalcoreMulti-country distribution agreement for rare disease portfolio including CRYSVITA (burosumab) for X-Linked Hypophosphataemia and Tumour-Induced Osteomalacia, and POTELIGEO (mogamulizumab) for cutaneous T-cell lymphoma. Distribution across Algeria, Iraq, Libya, and Jordan.
- Agios PharmaceuticalscoreDistribution agreement for PYRUKYND (mitapivat) commercialization in the Gulf Cooperation Council (GCC) region. NewBridge manages regulatory filings and commercialization of PYRUKYND for pyruvate kinase deficiency and thalassemia in GCC countries including Saudi Arabia, UAE, Kuwait, Qatar, Oman, and Bahrain.
- Hansa BiopharmacorePartnership to enable supply of Idefirix (imlifidase) for desensitization treatment in kidney transplantation to patients in MENA region, pending marketing authorization in respective MENA markets.
- BiogencoreDistribution agreement for certain Biogen Multiple Sclerosis products in selected MENA countries, ensuring continuity and improvement to access for long-term and life-changing neurological therapies.
- BeiGenecorePartnership for commercialization of BRUKINSA (zanubrutinib) for treatment of mantle cell lymphoma and other hematological malignancies in MENA region including Saudi Arabia, UAE, Kuwait, Bahrain, and Qatar.
- BioCryst PharmaceuticalscoreSupply and distribution agreement for ORLADEYO (berotralstat) for prevention of hereditary angioedema attacks in UAE, GCC countries, and Iraq. First targeted oral once-daily treatment for HAE patients.
- Pharming GroupcoreExclusive licence agreement for distribution of RUCONEST (conestat alfa) for treatment of acute hereditary angioedema in MENA region, including named patient supply and marketing.
- Sunovion Pharmaceuticals EuropecoreDistribution agreement for Latuda (lurasidone) for treatment of schizophrenia in adults across GCC region countries including Saudi Arabia, Kuwait, UAE, Qatar, Bahrain, and Oman.
- AramexminorLogistics partnership for pharmaceutical distribution including temperature-controlled storage and transportation of medication from UK and Canada to healthcare facilities in Middle East and Africa. Also manages logistics of patient samples for clinical testing.
- Avanzanite BioscienceminorRevenue-sharing partnership for Europe region for PYRUKYND commercialization, distinct from NewBridge's GCC partnership.
- AbbVieminorListed as partner on NewBridge Pharmaceuticals website.
- AlnylamminorListed as partner on NewBridge Pharmaceuticals website.
- UCBminorListed as partner on NewBridge Pharmaceuticals website.
- Jazz PharmaceuticalsminorListed as partner on NewBridge Pharmaceuticals website.
Scale indicators9 records
Recent moves7 records
Expansion highlights6 records
NewBridge Pharmaceuticals competitors and assessment
Company assessmentEmerging players
- ArriVent Biopharma: Emerging oncology-focused company; included only as an adjacent specialty pharma example.
- Er-Kim Pharmaceuticals: Turkey-based specialty pharma commercializing innovative therapies across MENA and CIS through licensing deals; comparable in niche therapy in-licensing model and regional commercialization footprint.
- Aspen Pharmacare: South African specialty pharma group with an emerging-markets commercialization model and portfolio of in-licensed or acquired brands; comparable to NewBridge's emerging-market specialty distribution strategy.
- Acino Pharmaceuticals: Switzerland-based specialty pharma focused on emerging markets including MENA, distributing in-licensed and proprietary products; comparable in out-licensing / partnership-driven distribution model.
Regional players
- Tabuk Pharmaceuticals: Saudi-headquartered pharma company partnering with global innovators for MENA distribution; aligned with NewBridge on strategic partnership model and regional therapeutic coverage.
- Benta Pharma: Lebanon-based pharma company with MENA distribution focus; comparable regional pharma platform with in-licensing and specialty distribution across the same markets.
- Julphar (Gulf Pharmaceutical Industries): UAE-based pharmaceutical manufacturer and distributor operating across the MENA region; comparable as a GCC-anchored pharma platform with a multi-country presence and product-portfolio strategy.
- SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corp.): Saudi-listed pharma company distributing branded and generic drugs across MENA; comparable in regional commercialization focus and presence in Saudi Arabia's regulated market.
Direct peers
- Hikma Pharmaceuticals: Jordan-headquartered specialty and branded pharmaceutical company with deep MENA distribution and an in-licensing model for innovative therapies; comparable to NewBridge in target market, business model, and therapeutic-area mix.
Broad incumbents
- Mundipharma: Global specialty pharma with strong MENA presence distributing partnered and proprietary products through independent associated companies; comparable in regional partnership network and specialty focus.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
NewBridge Pharmaceuticals social profiles
Digital presenceNewBridge Pharmaceuticals financial estimates
Financial estimateRevenue estimate
Valuation estimate
NewBridge Pharmaceuticals leadership team
Management profileNumber of profiles
Profiles9 records
NewBridge Pharmaceuticals funding detail
Funding detailFunding overview
Funding rounds2 records
Investors3 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NewBridge Pharmaceuticals M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NewBridge Pharmaceuticals
What does NewBridge Pharmaceuticals do?
NewBridge Pharmaceuticals is a specialty pharmaceutical commercialization platform that in-licenses, registers, and distributes FDA/EMA-approved innovative therapeutics from global pharma and biotech companies across the Middle East and North Africa. Its core activity is providing end-to-end regional commercialization — regulatory affairs, market access, medical affairs, sales and marketing, supply chain, pharmacovigilance, and quality compliance — for partner products spanning rare disease, oncology, hematology, neuroscience, immunology, gastroenterology, and genomics. The company also operates Early Access Programs that supply unregistered medicines to patients before local regulatory approval.
Is NewBridge Pharmaceuticals a public or private company?
NewBridge Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.
When was NewBridge Pharmaceuticals founded?
NewBridge Pharmaceuticals was founded in 2010. It employs 51 to 100 people.
Where is NewBridge Pharmaceuticals based?
NewBridge Pharmaceuticals is headquartered in Dubai, United Arab Emirates, in the Middle East region.
How does NewBridge Pharmaceuticals make money?
Two revenue lines are on record. Product Commercialization is the primary driver. The others are early Access Program.
Who are NewBridge Pharmaceuticals's main competitors?
Emerging players on record are ArriVent Biopharma, Er-Kim Pharmaceuticals, Aspen Pharmacare and Acino Pharmaceuticals. Regional players are Tabuk Pharmaceuticals, Benta Pharma, Julphar (Gulf Pharmaceutical Industries) and SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances Corp.). Hikma Pharmaceuticals is listed as a direct peer. Mundipharma is listed as a broad incumbent.
Does NewBridge Pharmaceuticals have an API?
No public API is recorded for NewBridge Pharmaceuticals.
What industry is NewBridge Pharmaceuticals in?
NewBridge Pharmaceuticals's product category is Specialty Pharmaceutical Commercialization. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIACAH, Nephrology & Urology Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.